STATEMENT
(08/09/2000)

1148 '00 NOV -9 P3:08

I, Jun Zhang, am well aware that I was nominated to be a member of the working groups by my Division Director, Frank Sistare. I am interested in doing the work. If I am selected, I will serve as a member as I can.

Jun Zhang
Division of Applied Pharmacology Research
CDER, FDA (HFD-910)

Jun Zhang

00N-0930

Nom 28

CURRICULUM VITAE

Name: Jun Zhang

Education:

1956 - 1961:	M.D., Beijing Medical University
1961 - 1964:	Master of Science in Medical Science, Department of Pathology, Beijing Medical University

Brief Chronology of Employment:

1987 - 1998	Special volunteer, Pathology Section, NHLBI, NIH
1988 - 1997	Visiting scientist, Toxicology and Pharmacology Branch, Division of Drug Research & Testing, CDER, FDA
1997 - 2000	Senior Staff fellow, Division of Applied Pharmacology Research (DAPR), CDER, FDA
2000 -	Pharmacologist, DAPR, CDER, FDA

Honors & Other Scientific Recognition:

1. **(1986)** Award for distinguished scientist, by Chinese National Scientific & Technical Committee, China.
2. **(1997)** On-spot Award Certificate, CDER, FDA.
3. **(1998)** Recognition Award, for Participation in the Initial Tg.AC Transgenic Mouse Carcinogenicity Dosing Studies. Office of Testing and Research (OTR), CDER, FDA.
4. **(1998)** FDA Outstanding Poster Award, 1998 FDA Science Forum, for phosphodiesterase III inhibitor-induced vasculitis in rats, Sigma Xi, The Scientific Research Society.
5. **(1999)** Special Recognition Award, for outstanding work in understanding the role of apoptosis-mediated cell loss in allograft heart valves, CDRH, FDA.
6. **(1999)** Certificate of Appreciation for outstanding innovative immunohistopathology assay developments that support a number of critical projects that are cross-cutting for the Division of Applied Pharmacology Research, OTR, CDER, FDA.
7. **(2000)** FDA Scientific Achievement Award, 2000 FDA Science Forum, for establishing animal models of insidious anthracycline induced cardiotoxicity, discovering a cardioprotective approach, and linking the cardiotoxicity to a monitorable interspecies biomarkers, Sponsored by FDA, Sigma Xi, and American Association of Pharmaceutical Scientists.
8. **(2000)** Certificate of appreciation for enormous, outstanding efforts in the histopathological assessment of drug-induced vascular lesions as well as support of photocarcinogenicity toxicity biomarker analysis effort, OTR, CDER, FDA.

SELECTED SCIENTIFIC PUBLICATION
RELEVANT TO THE WORKING GROUPS

1. Zhang J, and Wang YL (1984). **Immunohistochemical technique** of Con A receptor on paraffin-embedded, formalin-fixed tissue sections. *Chinese J. Pathol.* 13:103-104.

2. Zhang J, Yu ZX, Hilbert SL, Yamaguchi ML, Chadwick DP, Herman EH, and Ferrans VJ (1993). Cardiotoxicity of human recombinant interleukin-2 in rats: A morphological study. *Circulation.* 87:1340-1353. **(LYMPHOKINE-ACTIVATED KILLER CELLS)**

3. Zhang J, Yu ZX, Fujita S, Yamaguchi ML, and Ferrans VJ (1993). Interstitial dendritic cells of the heart: Quantitative and ultrastructural changes in experimental myocardial infarction. *Circulation.* 87:909-920.**(ANTIGEN-PRESENTING CELLS, IMMUNE EFFCTOR CELLS)**

4. Zhang J, Herman EH, and Ferrans VJ (1993). Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. *Am. J. Pathol.* 142:1916-1926. **(ANTIGEN-PRESENTING CELLS, IMMUNE EFECTOR CELLS)**

5. Zhang J, Herman EH, and Ferrans VJ (1994). Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats: Comparison with ICRF-187. *Toxicology.* 92:179-192.**(ANTIGEN-PRESENTING CELLS, IMMUNE EFFECTOR CELLS)**

6. Zhang J, Clark JR, Herman EH, and Ferrans VJ (1996). Doxorubicin-induced **apoptosis** in spontaneously hypertensive rats: Differential effects in heart, kidney and intestine, and inhibition by ICRF-187. *J. Mol. Cell Cardiol.* 28:1913-1943.

7. Yamamoto A, Wenthold RJ, Zhang J, Herman EH, and Ferrans VJ (1995). **Immunofluorescence techniques** for the identification of immune effector cells in rat heart: Application to the study of the myocarditis induced by interleukin-2. *J. Mol. Cell Cardiol.* 27:307-319.

8. Lovelance CIP, Zhang J, Vanek PG, and Collier GB (1996). Detecting **apoptotic** cells *in situ. Biomedical Products.* 21:76-77.

9. Guinee D, Fleming M, Hayashi T, Woodward M, Zhang J, Walls J, Koss M, Ferrans V, and Travis W (1996). Association of **p53** and **WAF1** expression with **apoptosis** in diffuse alveolar damage. *Am. J. pathol.* 149:531-538.

10. Zhou YF, Shou MT, Guetta E, Guzman R, Harrel RF, Yu ZX, Zhang J, Finkel T, and Epstein ES (1999).Cytomegalovirus infection of rats increases the neointimal response to **vascular injury** without consistent evidence of direct infection of the vascular wall. *Circulation.*100: 1569-1575. **(ATHEROSCLEROSIS, CYTOKINES, CAROTID BALLOON INJURY)**

11. Hirbert SL, Luna RE, Zhang J, Wang Y, Hopkins RA, Yu ZX, and Ferrans VJ (1999). Allograft heart valves: the role of **apoptosis**-mediated cell loss. *J. Thorac. Cardiovasc. Surg.*, 117:454-462.

12. Zhang J, Andrade ZA, Andrade SG, Takeda K, and Ferrans VJ (1999).

Apoptosis in a canine model of acute Chagasic myocarditis. *J. Mol. Cell Cardiol.* 31:581-596.

13. Zhang J, Duarte CG, Takeda K, and Ellis S (1999). Contrast medium- and mannitol-induced **apoptosis** in heart and kidney of spontaneously hypertensive rats. *Toxicol. Pathol.*, 27: 427-435.

14. Herman EH, Lipshultz SE, Rifai N, Zhang J, Papoian T, Yu ZX, Takeda K, and Ferrans VJ (1998). Use of **cardiac troponin-T** level as in indication of doxorubicin-induced cardiotoxicity. *Cancer Res.* 58:195-197.

15. Zhang J, Takeda K, Yu ZX, Herman E, Ferrans V (1998). Comparison of immunofluorescence labeling for **cardiac troponin T** (cTnT) and **troponin I** (cTnI) in doxorubicin-induced cardiomyopathy in spontaneously hypertensive rats. 1998 FDA Science Forum.

16. Herman EH, Zhang J, Lipshultx SE, Rifai N, Chadwick D, Takeda K, Yu Z-X, and Ferrans VJ (1999). Correlation between serum levels of **cardiac troponin-T** and the severity of the chronic cardiomyopathy induced by doxorubicin. *J. Clin. Oncol.* 7:2237-2243.

17. Zhang J, Vick JA, Whitehurst VE, Joseph X, Alleva FR, Chadwick D, and Hinton DM: assessment of albuterol-induced cardiotoxicity in normal and asthmatic rats by immunostaining for **cardiac troponin T** and **troponin I**. (In preparation).

18. Zhang J, Herman E, Chadwick D, Whitehurst J, Koerner J, Papoian T, Ferrans V, and Sistare F: Vascular toxicity in rats treated with the phosphodiesterase III inhibitor ASK&F 95654: evidence for endothelial cell activation, and mixed apoptotic and oncotic necrosis. *Am. J. Pathol.* (In revision) **(APOPTOSIS, ICAM-1, von WILLENBRAND FACTOR)**

19. Zhang J, Herman EH, Weaver JL, Chadwick DP, Broud D, Rosenzweig BA, Knapton AD, Whitehurst VE, Sistare FD (2000). Phsphodiesterase type III (PDE III) inhibitor induces **vasculitis** preceded by apoptosis in mesenteric vessels and lymphoid tissues of rat. 2000 FDA Science Forum.